BidaskClub upgraded shares of Tocagen (NASDAQ:TOCA) from a hold rating to a buy rating in a research report released on Saturday morning.
A number of other research analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Tocagen from a sell rating to a hold rating in a research report on Thursday, January 11th. ValuEngine raised shares of Tocagen from a strong sell rating to a sell rating in a research note on Friday, February 2nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $21.50.
Tocagen (NASDAQ TOCA) opened at $12.46 on Friday. The firm has a market cap of $271.59 and a PE ratio of -2.18. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.23 and a quick ratio of 5.23.
Several hedge funds have recently added to or reduced their stakes in TOCA. Vanguard Group Inc. purchased a new stake in shares of Tocagen during the second quarter worth about $5,036,000. BlackRock Inc. increased its stake in shares of Tocagen by 36.4% during the fourth quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after purchasing an additional 285,396 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Tocagen by 52.9% during the third quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock worth $7,886,000 after purchasing an additional 218,100 shares in the last quarter. Pure Financial Advisors Inc. purchased a new stake in shares of Tocagen during the fourth quarter worth about $1,324,000. Finally, Lake Street Advisors Group LLC purchased a new stake in shares of Tocagen during the fourth quarter worth about $1,042,000. 32.78% of the stock is owned by institutional investors and hedge funds.
WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.thestockobserver.com/2018/03/21/bidaskclub-upgrades-tocagen-toca-to-buy.html.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.